All In Biotech

Drug Trial Radar · NCT01905943

A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia

A Multicenter, Open-Label, Single-Arm, Phase IIIb, International Study Evaluating the Safety of Obinutuzumab Alone or in Combination With Chemotherapy in Patients With Previously Untreated or Relapsed/Refractory Chronic Lymphocytic Leukemia

Last checked: Nov 19, 2026Latest source record: Oct 28, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

979

Actual

Start

Nov 4, 2013

Primary completion

Dec 29, 2016

Study completion Oct 8, 2018

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Jul 23, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This multicenter, open-label, single-arm study will evaluate the safety and efficacy of obinutuzumab alone or in combination with chemotherapy in participants with previously untreated or relapsed/refractory chronic lymphocytic leukemia (CLL). This is a Post-Authorization Safety Study. Participants will receive 6 cycles of single-agent obinutuzumab or obinutuzumab in combination with chemotherapy at the investigator's discretion. Each participant will be followed until 30 months after the last participant has been enrolled. Total length of the study is anticipated to be approximately 5 years.

Conditions

  • Chronic Lymphocytic Leukemia

Interventions

  • BendamustineDrug

    Bendamustine: 90 milligram per millilitre square (mg/m\^2) IV over 60 minutes once daily (QD) Day 1-2 in participants previously untreated or 70 mg/m\^2 I.V. over 60 minutes QD Day 1-2 in participants with relapsed/refractory disease. In non-fit participants only, investigators may opt at their own discretion to use lower initial doses of bendamustine, i.e., bendamustine 70 mg/m\^2 in previously untreated participants, and bendamustine 50 mg/m\^2 in relapsed/refractory subjects (over 60 minutes qd Day 1-2 for each administration).

  • ChlorambucilDrug

    Chlorambucil 0.5 mg/kg p.o. qd on Day 1 and Day 15 in non-fit participants only.

  • CyclophosphamideDrug

    Cyclophosphamide 250 mg/m\^2 I.V. over 15-30 minutes qd Day 1-3 or Cyclophosphamide 250 mg/m\^2 p.o. QD Day 1-3 in fit participants only.

  • FludarabineDrug

    Fludarabine 25 mg/m\^2 I.V. over 30 minutes QD Day 1-3 or Fludarabine 40 mg/m\^2 per os (p.o.) QD Day 1-3 in fit participants only.

  • ObinutuzumabDrug

    Participants will receive obinutuzumab 1000 mg IV infusion on Days 1/2 (dose split over 2 consecutive days; 100 mg on Day 1 and 900 mg on Day 2), 8 and 15 of cycle 1, and on Day 1 of Cycles 2, 3, 4, 5, and 6. Each cycle is of 28-days duration.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse Events (AEs)Time frame: Baseline up to time of primary completion (3 years)
  2. Number of Participants With Adverse Events of Special Interest (AESIs)Time frame: Baseline up to time of primary completion (3 years)
  3. Number of Participants With Adverse Events of Particular Interest (AEPIs)Time frame: Baseline up to time of primary completion (3 years)

Locations

174 sites in 31 countries. Site status is shown where the registry gives one.

  • Hospital Iturraspe

    Santa Fe, Argentina

  • Hospital Erasme; Neurologie

    Brussels, Belgium

  • Cliniques Universitaires St-Luc

    Brussels, Belgium

  • Jessa Zkh (Campus Virga Jesse)

    Hasselt, Belgium

  • CHU Sart-Tilman

    Liège, Belgium

  • Sint Augustinus Wilrijk

    Wilrijk, Belgium

  • University Clinical Center of the Republic of Srpska, Clinic for Internal Disease, Hematology Dept

    Banja Luka, Bosnia and Herzegovina

  • University Clinical Center Sarajevo, Clinic for Hematology

    Sarajevo, Bosnia and Herzegovina

  • Hospital das Clinicas - UFRGS

    Porto Alegre, Rio Grande do Sul, Brazil

  • Hospital de Cancer de Barretos

    Barretos, São Paulo, Brazil

  • Hospital Amaral Carvalho

    Jaú, São Paulo, Brazil

  • Instituto de Ensino e Pesquisa Sao Lucas - IEP

    São Paulo, São Paulo, Brazil

  • Hospital Sirio Libanes; Centro de Oncologia

    São Paulo, São Paulo, Brazil

  • Hospital Estadual do Servidor Publico; Hematologia

    São Paulo, São Paulo, Brazil

  • Hospital das Clinicas - FMUSP; Hematologia

    São Paulo, São Paulo, Brazil

  • Hospital Santa Marcelina;Oncologia

    São Paulo, São Paulo, Brazil

  • CHU de Quebec - Hopital de l'Enfant-Jesus; Unite de Recherche en Hematologie et Oncologie

    Québec, Canada

  • Cancer Care Manitoba

    Winnipeg, Manitoba, Canada

  • Regional health authority A vitalite health network

    Moncton, New Brunswick, Canada

  • Queen Elizabeth II Health Sciences Centre; Oncology

    Halifax, Nova Scotia, Canada

  • Royal Victoria Regional Health Centre; c/o Oncology Clinical Trials

    Barrie, Ontario, Canada

  • Hopital Charles Lemoyne; Centre Integre de Lutte Contre Le Cancer de La Monteregie

    Greenfield Park, Quebec, Canada

  • Hopital Maisonneuve- Rosemont; Oncology

    Montreal, Quebec, Canada

  • Centre de sante et de services sociaux Rimouski Neigette

    Rimouski, Quebec, Canada

  • Saskatoon Cancer Centre; Uni of Saskatoon Campus

    Saskatoon, Saskatchewan, Canada

  • Cairo University Hospital Al Kasr El Ainy

    Cairo, Egypt

  • National Cancer Institute

    Cairo, Egypt

  • North Estonia Regional Hospital; Hematology

    Tallinn, Estonia

  • Tartu Uni Hospital; Hematology - Oncology Clinic

    Tartu, Estonia

  • Kuopio University Hospital

    Kuopio, Finland

  • Tampere University Hospital; Hematology

    Tampere, Finland

  • Turku Uni Central Hospital; Dept of Internal Medicine

    Turku, Finland

  • Hotel Dieu; Medecine D

    Angers, France

  • Ch Victor Dupouy; Hematologie

    Argenteuil, France

  • Hopital Augustin Morvan; Hematologie

    Brest, France

  • Hopital Cote De Nacre; Hematologie Biologique

    Caen, France

  • Chu Estaing; Hematologie Clinique Adultes

    Clermont-Ferrand, France

  • Hopital Henri Mondor; Hematologie Clinique

    Créteil, France

  • Chu Site Du Bocage;Hematologie Clinique

    Dijon, France

  • Centre Hospitalier Departemental Les Oudairies

    La Roche-sur-Yon, France

Showing 40 of 174 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.